~//bj.watch/overview
live

Latest signal

last curated pass Oct 26, 2026 · 8 public entries · source-aware summaries from 6 legacy curated cards plus llm-wiki tweets

# all # health # longevity # nutrition # sleep # concepts

Recent curated signals

Research claim “Extends the medium lifespan of male mice by 22.5% and 35% in female mice”: the IL-11 relay is a real, landmark Nature paper — but the female figure is wrong in the paper, wrong against Johnson’s own 2024 post, and the relay inherits a quote-post’s framing Johnson quote-posted Ryan Bethencourt’s same-age-mice photo (“the human equivalent of 85… the mouse on the right was given an antibody blocking a single inflammatory protein (IL-11) starting in late middle age”) with: “Extends the medium lifespan of male mice by 22.5% and 35% in female mice. It’s a few years old, I posted about it in 2024. Showed IL-11 as a driver of aging, and tissue inflammation and fibrosis. It climbed up with age, and was linked to fat build up and muscle loss. It is now in Phase II human clinical trials for lung fibrosis.” (1,048 likes, 51 reposts, 43 replies at curation; October 26, 21:41 UTC). The underlying work verifies in full: Widjaja et al., “Inhibition of IL-11 signalling extends mammalian healthspan and lifespan,” Nature, July 17, 2024 (10.1038/s41586-024-07701-9) — Il11 deletion extended lifespan in both sexes (24.9% averaged across genetic-deletion studies), and anti-IL-11 antibody (X203) from 75 weeks until death extended median lifespan 22.5% in males (130.3→159.6 weeks) and 25% in females (117.1→146.4 weeks), with fewer tumours at autopsy, improved metabolism and muscle function, and the ERK–AMPK–mTORC1 framing the post summarizes; the “Phase II human clinical trials for lung fibrosis” leg also verifies — Boehringer Ingelheim announced a Phase IIa trial of first-in-class IL-11 inhibitor BI 765423 in idiopathic pulmonary fibrosis on January 13, 2026, an asset in-licensed from the same Singapore/Duke-NUS lineage as the mouse work (Lassen Therapeutics’ LASN01 anti-IL-11-receptor antibody completed Phase 1/2a in pulmonary fibrosis and thyroid eye disease). But the relay misquotes its own source: the paper’s female figure is 25%, not 35%, and Johnson’s own July 17, 2024 post (“Treatment with anti-IL-11 from 75 weeks of age until death extends the median lifespan of male mice by 22.5% and of female mice by 25%,” with the same 105-week-old mouse photo) quotes it correctly — so the October 26 version degrades against both the paper and his own earlier post, the same class of transcription drift this dashboard recorded on the bone-pressure figure two days earlier. “Medium lifespan” for “median,” and the quote-post’s 85-human-year framing, are Bethencourt’s glosses; the post names no study. Boundaries: mouse antibody dosing and knockout genetics, no human longevity data; the IPF trial tests lung function, not aging endpoints; the photo pair is one representative image, not the survival curves. The dashboard records an attributed research relay with a verified paper and a drifted figure—not evidence for anti-IL-11 in humans, a drug expectancy, or medical advice. Research claim “Another win for psilocybin”: the feed relays a real three-day-old JAMA Psychiatry letter — while calling a 9-person uncontrolled subsample “9 Parkinson’s patients” and dropping every design limitation the authors state Johnson posted the feed’s first psychedelic-research relay: “Another win for psilocybin. In 9 Parkinson’s patients… GDF15 fell > 17.4% after 10 mg > 13.9% after 25 mg. High GDF15 signals mitochondrial failure and neurodegeneration. Inflammation also declined: > IL-6: −17% > IL-8: −20% > hsCRP: −9.6% > IL-10: +2.7% (anti-inflammatory)” (1,741 likes, 180 reposts, 79 replies; October 25, 14:18 UTC, with an attached figure). The study is real and the match is precise: Bradley, Kelley, et al., “Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson Disease,” JAMA Psychiatry research letter, published October 21, 2026 (10.1001/jamapsychiatry.2026.2733) — a secondary analysis of banked blood from the UCSF open-label pilot (NCT04932434; 12 participants with mild-to-moderate Parkinson’s plus depression/anxiety, 10 mg then 25 mg psilocybin with psychotherapy; Bradley et al., Neuropsychopharmacology 2025, 10.1038/s41386-025-02097-0), in which 9 of 12 gave samples, five inflammatory markers fell and were still significantly below baseline a month after the final dose, and the mitochondrial-stress marker GDF15 improved sharply right after dosing then lost the gain by longer-term follow-up. “High GDF15 signals mitochondrial failure and neurodegeneration” is a fair compression of why the marker was chosen (GDF-15 is elevated in mitochondrial disorders and in Parkinson’s serum). But the relay drops every limitation the letter and its authors state: single-arm, no control group, all participants knew they were receiving the drug, inflammatory markers move with sleep, stress, infection, and the depression that was lifting during hours of therapeutic attention; n=9 banked samples from a 12-person safety pilot; GDF15’s gain did not persist at follow-up while inflammation’s did; and co-author disclosures include psychedelic-industry ties. The “another win” framing converts an early biological signal the authors say needs controlled confirmation into a scoreboard result. Boundaries: psilocybin remains a Schedule I investigational substance; no dose, safety, or efficacy information for any reader; a randomized controlled trial (100 participants, UCSF + Yale, Michael J. Fox Foundation funding) is registered but not read out. The dashboard records an attributed research relay with a verified letter and dropped design context—not evidence psilocybin treats Parkinson’s, a psychedelic-use endorsement, or medical advice. Prevention “How to reduce microplastics”: the feed’s first standalone reader-directed microplastics checklist — each item traces to real food-contact microplastics literature, and the biggest caveats are dose and health outcome, not direction Johnson posted the feed’s first standalone microplastics-reduction directive aimed at readers’ environments: “how to reduce microplastics > glass or steel water bottle > never microwave food in plastic > wood cutting board > reverse osmosis water filter > loose leaf tea with stainless mesh” (4,855 likes, 190 reposts, 215 replies; October 25, 23:18 UTC). Each item traces to published measurement work: microwaving plastic containers releases by far the most microplastics and nanoplastics of any use scenario — up to 4.22 million microplastic and 2.11 billion nanoplastic particles per cm² in 3 minutes for some containers (Hussain et al., ES&T 2023, 10.1021/acs.est.3c04542s release; Environment & Health/ES&T 57:9782); plastic cutting boards shed an estimated 7.4–50.7 g/person-year of microplastics (polyethylene) — tens of millions of particles annually (Chen et al., ES&T 2023, 10.1021/acs.est.3c00924); plastic teabags steep at brewing temperature release on the order of 11.6 billion microplastics and 3.1 billion nanoplastics per cup in the canonical McGill measurement (Hernandez et al., ES&T 2019, 10.1021/acs.est.9b02540), and new head-to-head work finds bagged tea at 555–2,498 particles/cup vs 0.3–2.4 for bulk/loose leaf (Pehlivan & Gedik, npj Science of Food, October 13, 2026, 10.1038/s41538-026-01175-x) — the exact contrast behind “loose leaf tea with stainless mesh.” Glass/steel bottles and reverse-osmosis filtration are consistent with the same food-contact exposure framework; RO is also the filtration route Johnson’s own July sauna checklist and May microplastics-testing narrative already used. Boundaries: exposure-reduction logic is directional, but no study yet demonstrates that reducing these exposures improves human health outcomes — the health-effects literature is still predominantly association- and mechanism-level (cell/animal), and the ES&T cell studies are high-concentration in-vitro work; the checklist names no study; per-item effect sizes and rankings (which of the five moves exposure most) are not established; “never microwave food in plastic” is the strongest-supported single item. The dashboard records an attributed prevention checklist with verified measurement context—not a reader purchasing list, proven health-benefit evidence, or medical advice. Opinion “A biological attack is planned for Saturday”: the Halloween-sugar post is rhetoric built on a real number — ~600 million pounds of candy is the standard retail estimate, but every pathway from sugar to “neural reward blunting” is compressed and unattributed Johnson posted the feed’s most charged framing of the sugar narrative yet: “A biological attack is planned for Saturday. 600 million pounds of sugar laced with synthetic chemicals will enter the bodies of our children. Wreaking metabolic havoc, injuring vascular architecture, acidifying oral lining, releasing bacterial toxins, and blunting neural reward pathways. Instructing that gluttonous consumption of poison is celebratory.” (7,472 likes, 415 reposts, 510 replies; October 25, 15:33 UTC). The anchor number is the standard retail estimate: Americans buy roughly 600 million pounds of candy for Halloween each year (American Institute for Cancer Research; AP has used the same figure), and October 31, 2026 falls on a Saturday, so “Saturday” checks. The rest is rhetorical escalation of real-but-quiet directions: excess sugar consumption is associated with metabolic and cardiovascular risk and dental caries in the dietary-science literature (the AICR context for the same number is about processed-food calories and weight gain, not “attack” language); “acidifying oral lining” compresses the Stephan curve — sucrose fermentation drops plaque pH within minutes, driving caries — and “releasing bacterial toxins” gestures at endotoxin/LPS translocation literature that is far from established as a candy-season effect in children; “blunting neural reward pathways” compresses reward-system findings mostly demonstrated in rodent sugar-access models and human obesity neuroimaging, not trick-or-treaters. The post names no study, and “biological attack” converts a retail estimate into an adversarial frame — the same enemy-narrative register as the “don’t die” ideology’s death framing, now aimed at a holiday. Boundaries: engagement figures drift; children’s single-day candy consumption has no established acute “attack” consequence, and dietary guidelines treat added sugar as a chronic-exposure limit (≤10% of calories), not a poisoning event. The dashboard records an attributed opinion post with a verified anchor figure and compressed mechanisms—not a pediatric dietary directive, evidence that Halloween candy acutely injures children, or medical advice. Research claim “Mechanical pressure on shin bones extended mouse lifespan by 80 days (+9.4%)”: the figure looked untraceable for half a day — then Johnson self-corrected, and it resolves to a Cell Metabolism paper published the day before his post Johnson posted the feed’s first bone-mechanosensing longevity claim: “Mechanical pressure on shin bones extended mouse lifespan by 80 days (+9.4%). That’s the human equivalent of 7–9 yrs. Bone pressure triggers PIEZO1 sensors to broadcast anti-aging signals to the brain, liver, and immune system. If this translates to humans, my dunk training is flooding my entire body with anti-aging juice.” (2,538 likes, 156 replies, 141 reposts at re-curation; October 24, 01:28 UTC, with an attached paper screenshot). At first review the headline figure traced to no identified paper: the screenshot was Zhao et al., Aging Cell 2026 (10.1111/acel.70687), a Piezo1-agonist bone-mass study with no lifespan endpoint, and the nearest identical result — median lifespan 862→942 days, ~9%, females only — was Selman et al., Science 2009 (10.1126/science.1177221) on S6K1 knockout, with no mechanical loading. Twelve and a half hours later, Johnson replied to his own post: “Here is the correct paper for the stats in the original post. The paper above is also pro-dunk training. Mechanical pressure triggers PIEZO1 to release anabolic prostaglandin E2, which promotes bone formation and reduces resorption.” (50 likes, 6 replies, 2 reposts, 12,489 views; October 24, 13:53 UTC), attaching a screenshot OCR-identified as Bai et al., “Dynamic force sensing by bone delays aging and extends lifespan,” Cell Metabolism, published online October 23, 2026 — one day before the post (10.1016/j.cmet.2026.09.020). The figure now verifies: dynamic tibial axial loading (2 N at 2 Hz, 300 cycles, twice weekly) in mice at 20–24 months of age extended median lifespan by 9.4%/79.5 days (mean +11.9% females, +7.7% males), reversed bone-marrow immunosenescence, reduced liver steatosis, and improved cognition and endurance, with osteocyte-Piezo1 deletion accelerating whole-body aging and PEDF identified as a mechano-responsive anti-aging osteokine — covering the brain, liver, and immune triad the post named. The mechanism foundation verified last pass stands: osteocyte PIEZO1 bone anabolism (Li et al., eLife 2019, 10.7554/eLife.49631), a bone–brain axis (Cai et al., Nature Neuroscience, 10.1038/s41593-026-02422-w), and a mechano-bone-immune axis (Zhang et al., bioRxiv). The correction’s PGE2 sentence also traces, through the same research group’s mechanism work: loading-induced prostaglandin E2 release via Cx43 hemichannels promotes bone formation (Zhao et al., eLife 2022, 10.7554/eLife.74365) — a compressed but directionally accurate chain downstream of PIEZO1. The Selman match stands as coincidence, not source. Boundaries: one mouse study published one day before the post; the loader is an external calibrated device compressing an anesthetized tibia (2 N, 2 Hz, 300 cycles), not jumping, so dunk-training equivalence remains Johnson’s interpretation; the “human equivalent of 7–9 yrs” remains arithmetic on the mouse percentage; and no human loading evidence exists. The dashboard records an attributed research claim, an unusually fast self-correction, and a now-traced figure—not evidence that jumping or dunk training extends life, a reader exercise prescription, or medical advice. Prevention “Take earplugs everywhere”: Johnson issues the feed’s first standalone hearing-preservation directive — the brain-atrophy link is real, but “routinely above 85 dBA” overstates the measured record for the venues he names Johnson posted the feed’s first standalone hearing-preservation directive: “Take earplugs everywhere. Environments routinely above 85 dBA: > restaurants > sporting events > social gatherings > gym and theater > trains and subways > coffee shops. Can’t currently fix hearing loss. Hearing loss accelerates brain volume loss and cognitive decline.” (2,034 likes, 171 replies, 94 reposts; October 22, 21:41 UTC). The medical claims verify in direction: Lin et al. (NeuroImage, 2014, 10.1016/j.neuroimage.2013.12.059) followed 126 adults aged 56–86 in the Baltimore Longitudinal Study of Aging neuroimaging substudy for a mean 6.4 years and found speech-frequency hearing impairment independently associated with accelerated whole-brain atrophy (8.4 vs 7.2 cm³/year) and faster volume decline in the right temporal lobe — superior, middle, and inferior temporal gyri plus parahippocampus, the spoken-language regions; and the 2024 Lancet Commission on dementia prevention ranks hearing loss among its 14 modifiable risk factors (updated meta-analysis HR 1.37, n=666,370; 45% of dementia theoretically preventable across all 14), reporting hearing-aid use associated with 17% lower dementia risk and that the ACHIEVE randomized trial found a 48% three-year cognitive protective effect of hearing aids confined to its high-risk ARIC subgroup, with no overall effect in healthy volunteers. “Can’t currently fix hearing loss” is also accurate — noise-induced cochlear damage is permanent, and hearing aids and implants compensate without restoring normal hearing. The boundary: the “routinely above 85 dBA” venue list runs ahead of the measured record for the everyday venues it names — NYC mass-transit dosimetry (243 measurements) puts subway platforms at a mean 80.4 dBA with only about 20% of measurements exceeding 85 (a pilot survey averaged 86 dBA on platforms with 106–112 dBA maxima), while the largest restaurant-noise dataset (2,376 NYC venues crowd-measured via SoundPrint) averages 77–78 dBA with 25% of venues above 81 — conversation-hostile, but a single dinner at those levels sits far below the NIOSH 85-dBA 8-hour cumulative-dose concern, and 85 dBA is a workplace time-weighted limit, not a momentary danger line. The brain associations are observational — the BLSA authors discuss shared-neuropathology and reverse-causation alternatives — and no trial shows earplugs prevent cognitive decline (ACHIEVE tested hearing aids in people with hearing loss, not earplugs in normal-hearing people). The dashboard records an attributed prevention directive with verified literature and measured-noise context—not a reader audiology recommendation, a venue-by-venue noise assessment, evidence that earplug use prevents dementia, or medical advice. Rx safety “Your peptides may be coming [from] fentanyl suppliers”: Johnson relays a fully verifiable gray-market peptide safety warning — TRM’s vendor-overlap numbers, CBP’s master-carton seizures, and the first reported bootleg-retatrutide deaths Johnson relayed the feed’s first full consumer-protection warning about the gray-market peptide supply chain: “Your peptides may be coming fentanyl suppliers. Anhui Renchen Technology was indicted in 2023 for supplying the Sinaloa Cartel with fentanyl precursors. Their website currently sells semaglutide and melanotan II. Of roughly 200 Chinese firms TRM Labs tracked selling fentanyl precursors, at least 50 now sell peptides. The shipments enter the US in ‘master cartons’ mislabelled as snack food, broken up by a domestic handler and mailed on. CBP has intercepted around 400 of those operations and seized over 130,000 vials in the past year. FDA records surfaced showing two deaths, one in July and one in September, reported after people injected untested black market retatrutide.” (587 likes, 93 replies, 46 reposts; October 21, 21:48 UTC). Every checkable figure verifies against the underlying record: TRM Labs’ October 6 blockchain analysis identified 150+ Chinese chemical manufacturers accepting cryptocurrency with roughly 75% listing both peptides and fentanyl precursors, and crypto inflows to those dual-listing vendors rising from $28.2 million (2023) to $33.8 million (2024) to $37.3 million (2025) with about 57% of identifiable value from the United States; the “roughly 200 firms / at least 50 now sell peptides” framing is the Wall Street Journal’s count from TRM’s longer fentanyl-precursor tracker; Anhui Rencheng (ARTC) was charged by the DOJ in June 2023 and its site still listed semaglutide and Melanotan II alongside fentanyl-class chemicals as of September 2026; CBP’s Cincinnati port had intercepted 300+ master-carton operations by March and roughly 400 by the Journal’s October count, with 2,400+ seizures and 130,000+ vials nationally from October 2025 through August 2026; and the two deaths are the July FAERS report (41-year-old woman, cardiac arrest, product from an “unreliable source”) and September report (49-year-old patient, severe dehydration, malnutrition, cardiac arrest, vial from a “research use only” site) that CBS News reported on October 13 — the first public US death reports linked to bootleg retatrutide, with causation unverified. The boundaries: TRM cannot separate peptide revenue from precursor revenue, so no individual peptide purchase is traceable to trafficking; the deaths are adverse-event reports, not established causation; retatrutide itself is an unapproved investigational drug; Johnson names no source in the post, so the numbers are his transcription; and the warning lands adjacent to his commercial position — his Immortals Pharmacy sells peptides (the GLP-1 catalog promoted in July) as the regulated alternative, which the post leaves implicit rather than disclosing. The dashboard records an attributed safety relay with verified supply-chain context—not purchasing guidance, an indictment of all peptide use, evidence that regulated alternatives are risk-free, or medical advice. Methodology “My biomarker numbers say less than people think”: Johnson endorses an unnamed paper’s critique of his own N=1 method — and pitches the aging simulation he says comes next In the feed’s most self-critical methodology post, Johnson endorsed a new paper’s argument that the foundation of his own N-of-1 — biomarkers — captures less than his audience believes: “A new paper cites my N-of-1 as a core feature of next generation longevity science. It explains why my biomarker numbers say less than people think. I agree. Aging is a multi-scale physiological process that we can’t actually measure directly. Biomarkers are like the blind men touching the elephant; able to know a piece, but never the whole. The processes that dictate aging exist at multiple levels of biological complexity… Aging manifests differently among people, but in highly nuanced and often invisible ways. The static, cross-sectional measures the field is used to can only get us so far. N-of-1 initiatives like mine can capture some of this nuance, but ultimately fails at generalizability. The authors also critique N-of-1 as able to show ‘responsiveness but not durability; optimisation but not causality.’ The challenge, so far unmet, is modelling the complexity of aging in such a way that the output is not a forecast of biomarkers, but a simulation of aging system dynamics, i.e. one’s health trajectory into the future… A choose your own adventure where we can predict the consequences of both our healthy and unhealthy behaviors. This is exactly what we are aiming to build. If you’re into this as well, hit me up.” (317 likes, 52 replies, 14 reposts; October 21, 02:40 UTC). The epistemics are sound and echo the field’s own frameworks — a Cell framework review holds that no aging biomarker yet satisfies surrogate-endpoint validation, and even the strongest responsiveness work (the TranslAGE database of 51 interventional studies) tests whether biomarkers move under intervention, not whether moving them changes health outcomes. The boundaries: the paper is not identified in the post and is not linked, so the quoted critique — including “responsiveness but not durability; optimisation but not causality” — is his transcription of an unnamed source; “the static, cross-sectional measures the field is used to” understates a field that also runs longitudinal cohorts; and the closing pivot converts the limitation into a recruitment pitch for an aging-system-dynamics simulation that exists so far as stated intent — no model, publication, team, or validation is disclosed. The dashboard records an attributed epistemic-boundary endorsement with unverified source identity—not evidence that biomarker tracking is useless, a disclosed research program, or medical advice.

// Reference paths

Move from feed to dossiers

Each route keeps source trails and medical caution visible.
Protocol Health

Habits, Longterm, and Don’ts for measurement loops, sleep consistency, oral care, exercise, and experimental-intervention caution.

 Protocol Longevity

Habits, Longterm, and Don’ts for biomarkers, healthspan basics, critiques, and low-confidence immortality claims.

 Protocol Nutrition

Habits, Longterm, and Don’ts for plant-led meals, Blueprint products, microplastics claims, and metabolic-drug caveats.

 Protocol Sleep

Habits, Longterm, and Don’ts for bedtime discipline, front-loading examples, and metric caution from tweet-backed sources.

 Reference Concepts

39 source-aware glossary entries, including concepts without dedicated wiki pages yet.

 entity Blueprint

Blueprint is bryan-johnson's longevity protocol, product company, and public measurement system. It began as Project Blueprint, an N=1 effort to measure Johnson's organs and biological aging, and later became a consumer

 concept Blueprint Protocol

The Blueprint Protocol is bryan-johnson's closed-loop health system: measure body state, consult scientific evidence, implement interventions, measure again, and update. Johnson treats the body as a system whose organs a

 concept Don't Die

Don't Die is bryan-johnson's community slogan, longevity philosophy, and civilizational frame. The official Don't Die page describes a community “united in defeating all causes of human and planetary death and building a

 concept Biomarker-driven longevity protocols

A biomarker-driven longevity protocol is a health system that treats the body as a measurable control system: collect biomarkers, choose interventions, re-measure, and iterate. project-blueprint is the most visible curre

 Signal Metrics

Inspect source velocity by range, content type, and fallback API state.